Foundation for Research Development Board of Directors

FRD Board

Julia Barnes-Weise, J.D.

Julia Barnes-Weise, JD

Ms. Julia Barnes-Weise is the founder and executive director of the Global Healthcare Innovation Alliance Accelerator. She has been a visiting associate professor of the practice at Duke’s Sanford School of Public Policy and director of the Innovation, Technology and Policy Project as well as a consultant and lecturer for the Duke Law School Access to Medicines course.  Barnes-Weise is also a consultant to the WHO, the Coalition for Epidemic Preparedness and Innovation, and a frequent presenter at LES, LESI, AUTM and other conferences.

Barnes-Weise is a lawyer, entrepreneur and Certified Licensing Professional. She was formerly a director of business development at Glaxo Wellcome (now GSK), attorney at SAS Institute and has consulted for BioMatch LLC. Barnes-Weise has more than three decades of experience negotiating IP licenses, formulating alliance agreements and advising companies and institutions on partnering strategies.

She received a bachelor’s degree in economics and literature from Ohio Wesleyan University, a juris doctor degree from the University of North Carolina School of Law, completed a program in international trade from Notre Dame’s London Law Centre and studied international marketing through the Duke University and London Business School Joint International Marketing program.

Mark Currie, Ph.D.Mark Currie, Ph.D.

Dr. Currie brings world-leading R&D expertise across many disease areas including GI, having pioneered the discovery and development of LINZESS® (linaclotide) as well as the discovery and development of Ironwood’s leading GI development candidates, IW-3718 and MD-7246. He is president of Cyclerion Therapeutics, Inc. Prior to this role, he was most recently senior vice president, chief scientific officer and president of R&D at Ironwood. Prior to joining Ironwood, Dr. Currie directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor Inc. He also initiated, built and led discovery pharmacology and served as director of arthritis and inflammation at Monsanto Company, leading an effort that resulted in marketed COX‐2 inhibitors for the treatment of pain in humans and animals. Dr. Currie earned a Ph.D. in cell biology from the Bowman Gray Center for Medical Education at Wake Forest University and a B.S. in biology from the University of South Alabama.

Deb Geraghty

 Deborah Geraghty, Ph.D

Dr. Geraghty brings 20 years of extensive experience in the life sciences industry, serving in senior strategic, commercial,  portfolio positions and who is currently the COO at Anokion . Prior to Anokion, Deb was SVP, corporate strategy at Dimension Therapeutics, where she played a lead role in the company’s Series B financing and initial public offering, and was responsible for driving growth of the company’s portfolio prior to its successful IPO and recent acquisition by Ultragenyx Pharmaceutical Inc. Previous to Dimension, Dr. Geraghty was founder and vice president, project and portfolio development at Cydan Development, an orphan drug accelerator that raised $26 million to identify and de-risk assets with therapeutic and commercial potential. Prior, Dr. Geraghty was head of portfolio advancement at Aileron Therapeutics, where she led strategic growth and commercial efforts, and was director, new product marketing, at Infinity Pharmaceuticals. She also founded Back Bay Strategies, and held multiple positions at Kendall Strategies, Feinstein Kean Healthcare, and Genzyme Corp. Dr. Geraghty serves on the medical and scientific advisory board of Global Genes, a leading rare disease patient advocacy organization. She earned a BS in Biology at Union College, an MBA from the Carroll School at Boston College, and a PhD in Molecular Biology at the University of Vermont.

William Himmelsbach, MPH, FACHEWilliam Himmelsbach, MPH, FACHE

Bill Himmelsbach brings to FRD 36 years of leadership experience in the health care field, mainly with not-­for-­profit hospitals and multi-­hospital systems, including academic medical centers. In late 2012 he retired as the president & CEO of the Cardiovascular Research Foundation, a not-­for-­profit academic research organization based in New York City and affiliated with the College of Physicians and Surgeons at Columbia University. He remains on its Board and chairs the Audit Committee. He also chairs the governing board of Zucker Institute of Applied Neurosciences at MUSC and also serves on the Board at Beaufort (SC) Memorial Hospital, where he chairs its Finance Committee. Mr. Himmelsbach holds a B.A. in labor-­management relations from Penn State University and an MPH in health care administration from the University of Pittsburgh. He is a fellow of the American College of Healthcare Executives. He and his wife, Gail, are residents of Spring Island, SC.

Joseph C. McDonaldJoseph C. McDonald

Mr. Joseph McDonald is the president and CEO of Belimed Inc., a manufacturer of equipment for the medical and biopharmaceutical industries. Prior to his work at Belimed, McDonald was the president and COO of Berchtold Corporation and held a variety of senior management and leadership positions at Steris Corporation. He earned his business degree from Gannon University and completed executive business programs at both Columbia University and the University of Chicago.

Robert McQuade, Ph.D.Robert McQuade, Ph.D.

Dr. Robert D. McQuade is the executive vice president and chief strategic officer at Otsuka Pharmaceuticals Development and Commercialization. He joined Otsuka in 2004 and is responsible for guiding the strategic vision across its development profile and for its alliance partnerships. 

McQuade has extensive experience in the pharmaceutical industry and across the discovery, development and positioning of new drugs, especially for the treatment of serious mental illnesses. Prior to Otsuka, he held a variety of positions at Bristol-Myers Squibb and at Schering-Plough. McQuade earned his bachelor’s degree from Davidson College and a Ph.D. in biochemistry from the University of North Carolina.

Perry B. Molinoff, M.D.Perry B. Molinoff, M.D.

Dr. Perry Molinoff is a professor of pharmacology and the AN Richards professor of pharmacology emeritus at the University of Pennsylvania. He returned to a faculty position in the School of Medicine in 2007 after serving for three years as the vice provost for research at the University of Pennsylvania.

From 1981 through 1994, Molinoff was the AN Richards professor of pharmacology and the chairman of the department of pharmacology at the University of Pennsylvania. He earned his undergraduate and medical degrees from Harvard University and completed house officer’s training at the University of Chicago’s Hospitals and Clinics.

Arlene M. MorrisArlene M. Morris

Arlene M. Morris is the CEO of Willow Advisors, LLC, a biotech advisory firm. Ms. Morris was previously the chief executive officer and president of Syndax Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers from April, 2012 to May, 2015 and a member of the board of directors from May, 2011 to June, 2015. Prior to Syndax, Ms. Morris served as the president, chief executive officer and a member of the board of directors of Affymax, Inc. from 2003 to 2011, a publicly traded biotechnology company focused on peptides and development of therapies for renal disease. She has held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm; Coulter Pharmaceutical, Inc., a publicly traded oncology pharmaceutical company; Scios Inc., a publicly traded cardiovascular biopharmaceutical company; and Johnson & Johnson, a publicly traded healthcare company where she rose through the ranks to VP Business Development over a 15 year career. Ms. Morris is currently a member of the board of directors of Neovacs, SA, a French publicly traded biotechnology company and Palatin Technologies, Inc. and MiRagen both U.S. biopharmaceutical companies. She is also on the board of Viveve,
a publicly traded device company and previously served on numerous other boards including most recently the Dimension and Biodel Boards as well as the board of BIO. and the Humane Society of Silicon Valley. Ms. Morris received a B.A. in Biology from Carlow College.

Art Pappas, MBAArt Pappas, MBA

Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life science companies. Art founded Pappas Capital in 1994, and over the past twenty-four years the firm has managed more than $540 million in capital and invested in more than 75 life science companies through its flagship Pappas Ventures business unit, as well as its Specialized Fund Management business unit.

Art currently serves as a director for Arix Bioscience, Aura Biosciences and OrphoMed, and as a board observer for Amplyx Pharmaceuticals, Balance Therapeutics, CuraSen Therapeutics and Real Endpoints. Prior to founding Pappas Capital, Art held senior level leadership positions at several multinational pharmaceutical companies for which he was responsible for the development, licensing and launch of a number of global products. He was an executive member of the board of directors of Glaxo Holdings plc (NYSE: GLX, now GSK), and served as Glaxo’s chief executive responsible for international operations including research, development and manufacturing. Prior to Glaxo, Art was Vice President of Commercial Operations for Abbott International, and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. He previously served as Chairman and founding CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD) (acquired by Eli Lilly in 2017), and on the boards of Afferent Pharmaceuticals (acquired by Merck in 2016), Chimerix (NASDAQ: CMRX), Quintiles Transnational Corp. (NASDAQ: QTRN, now NASDAQ: IQV), TYRX (acquired by Medtronic in 2013), Syntonix Pharmaceuticals (acquired by Biogen IDEC in 2007), LEAD Therapeutics (acquired by BioMarin in 2010), CardioDx, and Embrex (NASDAQ: EMBX) (acquired by Pfizer in 2006). He also served as a board observer for Kezar Life Sciences (NASDAQ: KZR) and Plexxikon (acquired by Daiichi Sankyo in 2011).

Art is a member of the Board of Directors of the North Carolina Biotechnology Center, where he is a past chair, and the Medical University of South Carolina Foundation for Research Development. He is a member of the Board of Trustees of The Wistar Institute (a National Cancer Institute center), the Board of Advisors of the Duke Cancer Institute, and the Advisory Board of the BioExec Institute. He is also a member of the CEO Roundtable on Cancer and BayHelix, an organization of global life science community leaders. He previously served on the Board of Directors of the National Venture Capital Association. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK Special Warfare Center. Art received a BS in biology from The Ohio State University and an MBA in finance from Xavier University.

John Propst, PhD, MBA

John Propst, PhD, MBA

John Propst, PhD, MBA, is a Program Lead in the Medical Devices division of Verily Life Sciences (Google Life Sciences), an Alphabet, Inc. Company. He currently leads two key, big-pharma partnered, medical device projects aimed at empowering the patient and Health Care Provider with organized and actionable data. John’s projects are focused on developing low-cost, connected, micro-electronic devices that feed data into sophisticated care platforms leveraging Alphabet’s expertise in Artificial Intelligence and Neural Networks to provide meaningful insights. John left his Associate Director of Business Development position in Technology Commercialization at the University of South Carolina’s Office of Economic Engagement to pursue a career in Silicon Valley. He began at Apple, where he worked as a Strategic Operations Manager working in global iPhone operations, on-boarding new to Apple final manufacturers in Asia. He gained insight into how Apple was able to manufacture such a high quality product, at incredible volumes, with high reliability and reproducibility. His second role at Apple was working on the Apple Watch team as a Product Design Engineering Program Manager. He lead the Health Technologies team who developed and later launched the ECG Sensor on the Apple Watch Series 4. John grew up in South Carolina and went to Erskine College for his undergraduate degree in Biochemistry. He then earned his PhD in Biomedical Engineering at the University of South Carolina. During the second year of his PhD, he concurrently enrolled in the University to pursue and later earned an MBA from the Darla Moore School of Business. He was always passionate about the marriage of science and business and was determined to work at the intersection between the laboratory benchtop and the consumer. After his PhD, along with his PhD mentors, he co-founded a startup company in emergency medicine and critical care focused on treatments that prevented multi-organ failure and death due to hypovolemic shock after trauma.

Paul Williamson, M.D.Paul Williamson, M.D.

Dr. Paul Williamson earned his bachelor’s and master’s degrees from the University of Massachusetts. He completed a medical residency at the St. Vincent Hospital in Worcester and a rheumatology fellowship at the Hospital of the University of Pennsylvania in Philadelphia. Williamson is a board-certified internist and rheumatologist. In addition to practicing rheumatology in Massachusetts, he was the chief of medicine at the Union Hospital Campus of the North Shore Medical Center, the medical director of the North Shore Medical Group Inc., a member of the executive committee of Charter Professional Services Corporation, a subsidiary of Partners HealthCare System, and a member of Partners HealthCare Chiefs’ council.

Williamson joined the Johnson & Johnson Family of Companies in 2001 and left in 2014 to individually pursue the development of and investment in early stage technologies to satisfy unmet medical needs. He currently serves on the advisory board of the Innovation Support Center of Harrington Discovery Institute, where he advises university-based physician scientists on accelerating the development of their inventions toward commercialization. In addition, Williamson is actively involved with Charleston Angel Partners as an investor in early stage technologies within the life sciences.

MUSC Appointed Members

Terri BarnesTerri Barnes

Ms. Barnes, a native of Rock Hill, South Carolina, was elected to the MUSC Board of Trustees in 2014 as the lay representative from the Fifth Congressional District. Ms. Barnes graduated from Clemson University in 1981 with a B.S. degree in Therapeutic Recreation. She started her professional career with the National Muscular Dystrophy Association (MDA) as a patient service coordinator. Among her many responsibilities with MDA, she represented South Carolina at the annual Jerry Lewis Telethons. After working with the MDA, Ms. Barnes began a new career path in the computer industry. She is currently Vice President of Applied Data Technologies which she co-founded in 1998. The company has grown into a leading top-tier reseller of Hewlett Packard products. Ms. Barnes has served on many panels and advisory boards with the Hewlett Packard Company. She is an active member of First Baptist Church of Rock Hill, where she serves as a youth Sunday school teacher. Ms. Barnes and her husband, Ruck, have three children and one grandchild.

Kathleen T. Brady, M.D., Ph.D.

Kathleen T. Brady, M.D., Ph.D.

Dr. Brady is a board-certified psychiatrist, distinguished university professor, and vice president for research and director of the South Carolina Clinical & Translational Research (SCTR) Institute at the Medical University of South Carolina. Her research focuses on substance use and posttraumatic stress disorder, with an emphasis on translating study findings into effective treatment interventions. Dr. Brady has authored more than 350 publications, is a world-class lecturer and has received several meritorious awards for her dedication.

Nancy DeMore, M.D., FACSNancy DeMore, M.D., FACS

Dr. DeMore is a surgical oncologist with 20 years of experience in tumor angiogenesis and translational research. She received her training in general surgery at Boston University, during which she did a three-year surgical research fellowship under the mentorship of Dr. Judah Folkman at Harvard Medical School. 

After completing her general surgery residency, Dr. DeMore trained at Memorial Sloan-Kettering Cancer Center for a fellowship in Surgical Oncology from 1999-2001. She was professor of surgery at the University of North Carolina at Chapel Hill from 2001-2014, where her clinical practice focused on breast surgical oncology, and was PI or co-investigator on 30 clinical trials. The NIH has funded Dr. DeMore since 2001, and her research program has focused on the discovery of novel angiogenesis targets and subsequent drug development. She currently serves on the NIH Cancer Immunopathology and Immunotherapy Study Section.

Dr. DeMore is presently professor and interim chief of surgical oncology, medical director of the MUSC Breast Center, BMW-endowed chair in cancer research, and vice chair of entrepreneurship at MUSC. She is also co-founder and chief scientific officer of Enci Therapeutics, a biotech start-up company.

Jesse GoodwinJesse Goodwin, Ph.D.

Dr. Goodwin is the Chief Innovation Officer for the Medical University of South Carolina. Prior to this role, Dr. Goodwin was the Vice President of Development for the Zucker Institute for Applied Neurosciences (ZIAN), a technology accelerator serving the Neurosciences at MUSC and had also served as the Deputy Director of the MUSC Foundation for Research Development (FRD). In these capacities, she effectuates the translation of university innovations into products and services that improve health and patient care through her ability to strategically plan across multiple aspects of an innovation pipeline and to earn the trust of stakeholders necessary to coalesce support and build collaborations.
 
Dr. Goodwin came to MUSC from a Boston-based intellectual property (IP) consulting firm where she was Director of the Medical Device division, providing insight to client companies on IP matters pertaining to a vast array of medical technologies. Dr. Goodwin completed a post-doctoral fellowship in the Harvard-MIT Health Sciences and Technology program. She holds a Ph.D. in Biomedical Engineering from Stony Brook University.

Kenneth Ruggiero, Ph.D.

Kenneth Ruggiero, Ph.D.

Dr. Ruggiero is professor and co-director of the Technology Applications Center for Healthful Lifestyles (TACHL), as well as director of the Telehealth Resilience and Recovery Program. He received his bachelor’s degree in psychology from the State University of New York at Buffalo and master’s degree and Ph.D. in clinical psychology from West Virginia University. He completed his internship and NIH-funded postdoctoral fellowship at MUSC.

Dr. Ruggiero's work centers on the development, evaluation, and dissemination of technology-based interventions to improve population mental health. This includes research on brief, self-help interventions for disaster victims as well as stepped care approaches for survivors of traumatic injury. A second major line of his work aims to improve quality of care in community mental health service settings through the development of scalable, technology-enhanced activities for providers. Dr. Ruggiero has had continuous extramural funding from the National Institutes of Health since 2001.

As principal investigator, he has led more than a dozen grants funded by NIH, VA and Department of Homeland Securities, and has served as co-investigator on numerous grants funded by DoD, NIDA, and SAMHSA. Dr. Ruggiero has more than 150 scholarly publications and 180 presentations, and has served as a formal mentor to dozens of trainees and faculty members. He is a standing member of an NIH review panel and serves on four editorial boards.

Lisa Saladin, PT, Ph.D., FAPTALisa K. Saladin, PT, Ph.D., FAPTA

Dr. Lisa Saladin is currently the Executive Vice President for Academic Affairs and Provost at the Medical University of South Carolina (MUSC). In this capacity, she serves as the chief academic officer of the university with administrative oversight and leadership over all six colleges (Medicine, Dental Medicine, Pharmacy, Nursing, Health Professions, and Graduate Studies), Hollings Cancer Center, the Offices of Research, Education and Student Life, Gender Equity, and the MUSC Library. She manages a total budget of approximately 40 million dollars and supervises 18 direct reports. Prior to serving in this role, Dr. Saladin was Dean of the College of Health Professions at MUSC where she has been a faculty member for the last 27 years. As Dean, she led a faculty and staff of nearly 140 individuals, directed a budget of approximately 34 million dollars, and provided oversight of nine academic programs. Dr. Saladin earned a Bachelor of Medical Rehabilitation (Physical Therapy) and a Master of Science in Anatomy (Neuroscience) from the University of Manitoba in Canada and a Doctor of Philosophy in Physical Therapy from Nova Southeastern University in Florida.

Dr. Saladin’s clinical expertise is physical therapy for individuals with neurological disorders, and her research interests are racial and gender disparities in access to care, community-based service learning, and motor control and treatment outcomes for individuals with neurological disorders. Dr. Saladin is best known for her excellence as an educator. She has experience in curriculum development, inter-professional education, distance education, and development of innovative methods to engage and motivate students to learn. She has been widely recognized for her teaching excellence with three University Health Sciences Teaching Excellence Awards, a South Carolina Governor’s Distinguished Professor Award, and a 2009 MUSC Master Teacher designation. In 2008, she was recognized nationally for her teaching excellence by the American Physical Therapy Association (APTA) and received the Award for Excellence in Academic Teaching.

Dr. Saladin serves on the board of the MUSC Foundation for Research Development; as Vice-President and a board member of the American Physical Therapy Association; and as Chair of the APTA Public Policy and Advocacy Committee. As Chair of this committee, she receives monthly updates on national healthcare policy issues and is actively engaged in payment reform, new healthcare delivery models, telehealth, and legislative advocacy. She meets regularly with legislators and policy makers in DC and has been invited to make national presentations on healthcare reform and the future of healthcare.

Charles SchulzeCharles Schulze, CPA

Mr. Schulze, a native of Greenwood, was elected to the MUSC Board of Trustees in 2002, as the lay representative from the Third Congressional District. Mr. Schulze is the current Chairman of the MUSC Board of Trustees. He graduated from Georgia Military Academy, received his BBA degree in accounting from the University of Georgia and a master’s degree in accounting from the University of South Carolina.  Mr. Schulze served in the United States Air Force for four years. He served in the Far East and Southeast Asia for three years. He is a veteran of the Vietnam War and the Cold War with service in Korea and Taiwan. Among his decorations are four Outstanding Unit awards with "V" device for Combat Support Valor.  Mr. Schulze is a retired shareholder in a regional accounting and consulting firm. He currently practices in the Financial Forensic area as an investigator and an expert in financial forensics. He is a past Distinguished Lecturer at the University of Georgia. He is a former President of the SC Association of CPAs and a former member and chairman of the SC Board of Accountancy. Mr. Schulze and his wife, Sarah Allice, live in Greenwood and have two daughters.

Michael Yost, Ph.D.

Michael Yost, Ph.D.

Dr. Michael Yost is the associate chairman for research at MUSC and director of research for general surgery, trauma and critical care surgery. He is responsible for all facets of the research effort in the department of surgery, division of general surgery and acute care including recruitment, personnel management, budget management and control, scientific direction, funding procurement and intellectual property.

Dr. Yost has significant startup and industrial experience. He was the vice chairman of Vitasol LLC, a biotech startup company that specializes in novel resuscitative fluids and strategies. Dr. Yost also spent more than 15 years as a research and process engineering manager. He has more than 70 publications and 13 patents and patent applications in the areas of tissue engineering and resuscitation.

Ex-Officio Member

Lawrence S. Olanoff, M.D., Ph.D.Lawrence S. Olanoff, M.D., Ph.D.

Dr. Larry Olanoff is special advisor to the President for Corporate RelaQons at MUSC. AUer a long career in the pharmaceuQcal industry, he reQred from his last posiQon as President and COO at Forest Laboratories Inc., and served as a director of Forest Laboratories Inc. unQl 2014. Dr. Olanoff was President and CEO of Celsion CorporaQon from 2005 to 2006. From 1995 unQl 2005, he was the ExecuQve VP of ScienQfic Affairs for Forest Laboratories. From 1993 to 1995, Dr. Olanoff was the Senior VP of Clinical Research and Development at Sandoz PharmaceuQcal CorporaQon. From 1984 to 1993, he was employed by the Upjohn Company, where his last posiQon was Corporate VP of Clinical Development and Medical Affairs.

Dr. Olanoff holds a master’s degree and Ph.D. in biomedical engineering from Case Western Reserve University and was a medical resident and clinical pharmacology fellow at MUSC. He is board-­‐cerQfied in clinical pharmacology and is the author or co-­‐author of numerous scienQfic publicaQons in the fields of clinical pharmacology, drug delivery and pharmacokineQcs. Dr. Olanoff currently serves as an advisor to the Harrington Discovery InsQtute and is a member of the scienQfic advisory boards of BioMoQv, and a number of pharmaceuQcal and biotech firms. He is a board member of Ironwood PharmaceuQcals and Mitochondria in MoQon Inc., as well as several local nonprofit organizaQons serving biomedical research. Dr. Olanoff is the founder of the Technology Accelerator Company, a nonprofit organizaQon that supports biomedical research innovaQons in SC.

Emeritus Members

Dan D. Adams, J.D. Daniel D. Adams, JD

 Mr. Daniel Adams is the executive chairman of Protein Sciences Corporation. He previously founded and managed Advanced Genetic Sciences Inc.,  Biogen Idec, AlleRx and Plant Genetic Systems. Adams holds a bachelor’s degree in chemistry from Cornell University and a juris doctor degree magna  cum laude from New York University School of Law.

Harold E. Chappalear, LLD (Hon.)

Harold E. Chappelear, LLD (Hon.)

Hal Chappelear is a native of Greenville, South Carolina. He holds a Bachelor of Science in Pharmacy from the Medical University of South Carolina and a Doctor of Laws (honoris causa) from the University of Maryland.  Additionally, he completed postgraduate work in psychology and economics at Jacksonville University and the University of Florida.

After participating in the private practice of pharmacy at Community Drug Store and St. Francis Hospital in Greenville, South Carolina, Hal joined The Upjohn Company [Now Pfizer Inc. (NYSC: PFE)] as a sales representative in Anderson, South Carolina in 1962. He became a member of the company's management ranks in 1967 and throughout the years that followed, held numerous positions which included responsibility for North American Operations, Worldwide Marketing Support, and External Affairs. He was a member of the Corporate Management Office, a group of eleven officers responsible for directing the business of The Upjohn Company. He retired from Upjohn September 1, 1992, as a Corporate Executive Vice President.

In October of 1992, Hal joined Medicis Pharmaceutical Corporation [Now Valeant Pharmaceuticals International, Inc. (NYSE VRX)] currently based in Bridgewater, New Jersey. He served Medicis as President, Chief Operating Officer, and member of the Board of Directors until June 1995. In April 1993, he was appointed Affiliate Professor in the School of Pharmacy at the University of Maryland, Baltimore.

Hal is now a Principal of InternaSource LLC (www.internsource.com) and Member of the Board for Gregory Pharmaceuticals Holdings (GPH), Bristol Tennessee. GPH is a private Company owned by the Gregory family (major stockholders), the University of Maryland Baltimore, Hal Chappelear, and other minor investors. One of GPH’s holdings is UPM Pharmaceuticals (www.upm-inc.com) an independent contract research, development, and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology industries. Following his leadership with support of Dean Knapp and others in the School, UPM had its beginning in The University of Maryland’s School of Pharmacy.
As a Principal of InternaSource LLC, he is a private consultant for small businesses, religious, non-profit and academic institutions. In this capacity, he is engaged in General Business Management, Strategic Planning, Humble Leadership Development, Personal Counseling, and Executive Coaching. He is (or has been) affiliated with South River Restoration, Cell Works (Cancer Research), Dyad Pharmaceuticals (Biotech), University of Maryland Baltimore (School of Pharmacy, School of Medicine and School of Dentistry), Medical University of South Carolina (School of Pharmacy, School of Dentistry and Foundation for Research Development) and American Society of Health-System Pharmacists.

Hal Chappelear serves on the Board of Trustees of the University of Maryland Baltimore Foundation, Inc., Board of Directors, University of Maryland Baltimore Health Sciences Research Park Corporation, Board of Visitors of the School of Pharmacy, University of Maryland Baltimore, School of Pharmacy, Medical University of South Carolina and Advisor to President and CEO of the Severn Leadership Group (https://www.severnleadership.net/). He has served on the Advisory Boards of the University of Georgia, University of Nebraska, University of Florida, and University of Arizona, Board of Directors of the Severn Leadership Group, Foundation for Critical Care Medicine, the Kalamazoo Symphony Society, the Research and Education Foundation of the American Society of Health-System Pharmacists (ASHP) and the Health Sciences Foundation of the Medical University of South Carolina.

On July 17, 2002, the United States Coast Guard Licensed Dr. Chappelear as a U. S. Merchant Marine Officer.

On March 29, 2006, Hal was inducted into the Beta Chi chapter of Phi Lambda Sigma at the Medical University of South Carolina. Phi Lambda Sigma is an honor society focused on Pharmacy Leadership.

His biographical sketch has been published in Marquis Who's Who in America and Who's Who in Finance and Industry.

Hal Chappelear and his wife Billie currently reside in Annapolis, Maryland. They have two children: Alan Todd (deceased) and Amy Elizabeth of Millersville, Maryland.
 

Carl Ehmann, M.D.Carl Ehmann, M.D.

Dr. Carl Ehmann received a bachelor’s degree and a master’s degree from State University of New York at Buffalo. He has held academic appointments at the University of Pennsylvania, Wake Forest University, New York University and the University of Minnesota. 

Dr. Ehmann is a former chairman of the FRD board of directors. During his career, he was the research and development leader of several large multi-national companies including Bristol-Myers (Dermatology), Johnson & Johnson Consumer Products Company, Reynolds Technology Inc. and Reckitt & Coleman. Dr. Ehmann began his industrial research career at Hoffmann-LaRoche Pharmaceutical Company.

Layton McCurdy, M.D.Layton McCurdy, M.D.

Dr. Layton McCurdy served as president of the American Board of Psychiatry and Neurology from 1990 to 1991, president of the American College of Psychiatrists from 1993 to 1994, and president of the Association of Chairmen of Departments of Psychiatry from 1979 to 1980.

McCurdy currently serves as a member of the board of advisors at CureSource Inc. He has participated in national advisory positions for the Department of Veterans Affairs and for the National Institute of Mental Health (NIMH), where he was a presidential appointee to the NIMH Advisory Council from 1978 to 1982. McCurdy is dean emeritus and professor of Psychiatry and Behavioral Sciences at MUSC.